Back to BSX Overview
NYQ · Valuation Lab
BSX
Boston Scientific Corporation
Last$47.74
Market cap69.2B
EV/EBITDA14.4x
Intrinsic value
$46.93
MoS -1.7% · Fairly Valued
Assuming 11.7% FCF margin and 7.5% Y1–5 growth.
Upside to price
EV (DCF)80.1B
Terminal share70%
Expected IV$50.73
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 70% of EV
PV of stage FCFs24.4B
PV of terminal value55.7B
Enterprise value80.1B
Net cash / (debt)-12.1B
Equity value68B
Intrinsic value / share$46.93
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 22.6B | 2.6B | 2.5B | 93.8% |
| Y2 | 24.3B | 2.8B | 2.5B | 88.0% |
| Y3 | 26.1B | 3.1B | 2.5B | 82.5% |
| Y4 | 28B | 3.3B | 2.5B | 77.4% |
| Y5 | 30.1B | 3.5B | 2.6B | 72.6% |
| Y6 | 31.3B | 3.7B | 2.5B | 68.1% |
| Y7 | 32.5B | 3.8B | 2.4B | 63.8% |
| Y8 | 33.7B | 3.9B | 2.4B | 59.9% |
| Y9 | 35B | 4.1B | 2.3B | 56.2% |
| Y10 | 36.3B | 4.2B | 2.2B | 52.7% |
| Terminal | — | — | 55.7B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.